Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

BACKGROUND: We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified. METHODS: Pretreatment FFPE tumor specimens (n = 26) were stained for CD8, PD-L1, and PD-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Giraldo, Nicolas A., Nguyen, Peter, Engle, Elizabeth L., Kaunitz, Genevieve J., Cottrell, Tricia R., Berry, Sneha, Green, Benjamin, Soni, Abha, Cuda, Jonathan D., Stein, Julie E., Sunshine, Joel C., Succaria, Farah, Xu, Haiying, Ogurtsova, Aleksandra, Danilova, Ludmila, Church, Candice D., Miller, Natalie J., Fling, Steve, Lundgren, Lisa, Ramchurren, Nirasha, Yearley, Jennifer H., Lipson, Evan J., Cheever, Mac, Anders, Robert A., Nghiem, Paul T., Topalian, Suzanne L., Taube, Janis M.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6167897/
https://ncbi.nlm.nih.gov/pubmed/30285852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0404-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados